RT Journal Article
SR Electronic
T1 Bevacizumab and Postoperative Wound Complications in Patients with Liver Metastases of Colorectal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2255
OP 2261
VO 35
IS 4
A1 HIROFUMI UTSUMI
A1 YOSHITAKA HONMA
A1 KENGO NAGASHIMA
A1 SATORU IWASA
A1 ATSUO TAKASHIMA
A1 KEN KATO
A1 TETSUYA HAMAGUCHI
A1 YASUHIDE YAMADA
A1 YASUHIRO SHIMADA
A1 YOJI KISHI
A1 SATOSHI NARA
A1 MINORU ESAKI
A1 KAZUAKI SHIMADA
YR 2015
UL http://ar.iiarjournals.org/content/35/4/2255.abstract
AB Aim: The present study investigated whether bevacizumab (BV) is associated with postoperative wound complications (PWCs). Patients and Methods: We retrospectively analyzed patients undergoing surgery for liver metastases of colorectal cancer at our Institution. Patients were divided into 3 groups according to the preoperative treatment: che mo therapy with BV (group A), chemotherapy without BV (group B) and no chemotherapy (group C). Results: Between February 2003 and September 2012, 297 patients underwent 373 surgeries. Groups A, B and C consisted of 23, 62 and 288 patients, respectively. PWCs occurred in 29 patients (7.8%). In multivariate analysis, there were no differences in PWCs among the groups (C vs. B:P=0.739; C vs. A: P=0.110). Conversely, lower serum albumin levels (<3.5g/dl vs. ≥3.5g/dl: p=0.030) and synchronous colorectal resection (no vs. yes; p<0.001) remained significant risk factors of developing PWCs. Conclusion: Chemotherapy with or without BV did not influence the risk of PWCs.